Novo Nordisk | NVO - Assets


Novo Nordisk reported DKK76.18B in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
ANI Pharmaceuticals USD 1.41B 65.15M Sep/2025
Aurora Cannabis CAD 756.86M 80.98M Sep/2025
Bausch Health Companies USD 26.37B 458M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Canopy Growth CAD 1.07B 165.17M Sep/2025
Corcept Therapeutics USD 836.65M 13.04M Dec/2025
Drreddys Laboratories INR 6.26B 161.9M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Novo Nordisk DKK 542.9B 30.61B Dec/2025
Novo Nordisk DKK 76.18B 412.98B Jun/2025
Pacira USD 1.3B 239.68M Sep/2025
Perrigo USD 10.08B 10.1M Sep/2025
Phibro Animal Health USD 1.41B 20.03M Dec/2025
Prestige Brands USD 3.49B 52.46M Dec/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Supernus Pharmaceuticals USD 1.45B 32.89M Dec/2025
Zoetis USD 15.47B 308M Dec/2025